| Bioactivity | Frexalimab (SAR441344; INX-021) is a monoclonal antibody targeting the CD40 ligand (CD40L). Frexalimab has the potential for multiple sclerosis research[1]. |
| Name | Frexalimab |
| CAS | 2515463-86-0 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Bruce A C Cree, et al. New drugs for multiple sclerosis: new treatment algorithms. Curr Opin Neurol. 2022 Jun 1;35(3):262-270. |